Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Matthew Steven Davids, M.D.


This page shows the publications co-authored by Matthew Davids and Stephen Chong.
Connection Strength

  1. Breaking through BCL-2 inhibition in CLL. Blood. 2020 03 05; 135(10):709-711.
    View in: PubMed
    Score: 0.887
  2. BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood. 2021 Jun 24; 137(25):3495-3506.
    View in: PubMed
    Score: 0.243
  3. Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. Nucleic Acids Res. 2020 12 16; 48(22):12727-12745.
    View in: PubMed
    Score: 0.234
  4. Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica. 2021 08 01; 106(8):2251-2256.
    View in: PubMed
    Score: 0.061
  5. The redox-senescence axis and its therapeutic targeting. Redox Biol. 2021 09; 45:102032.
    View in: PubMed
    Score: 0.060
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.